Novo Nordisk AS (NONOF)
115.70
-0.56
(-0.48%)
USD |
OTCM |
Oct 17, 15:56
Novo Nordisk Price to Book Value: 31.88 for Oct. 17, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 16, 2024 | 32.03 |
| October 15, 2024 | 33.67 |
| October 14, 2024 | 32.94 |
| October 11, 2024 | 33.43 |
| October 10, 2024 | 32.45 |
| October 09, 2024 | 31.83 |
| October 08, 2024 | 31.89 |
| October 07, 2024 | 32.51 |
| October 04, 2024 | 31.42 |
| October 03, 2024 | 31.42 |
| October 02, 2024 | 32.38 |
| October 01, 2024 | 32.59 |
| September 30, 2024 | 32.13 |
| September 27, 2024 | 32.73 |
| September 26, 2024 | 35.27 |
| September 25, 2024 | 34.45 |
| September 24, 2024 | 35.27 |
| September 23, 2024 | 34.31 |
| September 20, 2024 | 34.76 |
| September 19, 2024 | 36.69 |
| September 18, 2024 | 36.77 |
| September 17, 2024 | 36.31 |
| September 16, 2024 | 38.03 |
| September 13, 2024 | 37.61 |
| September 12, 2024 | 38.10 |
| Date | Value |
|---|---|
| September 11, 2024 | 36.25 |
| September 10, 2024 | 35.45 |
| September 09, 2024 | 35.83 |
| September 06, 2024 | 36.80 |
| September 05, 2024 | 35.95 |
| September 04, 2024 | 37.55 |
| September 03, 2024 | 38.17 |
| August 30, 2024 | 38.24 |
| August 29, 2024 | 37.26 |
| August 28, 2024 | 36.95 |
| August 27, 2024 | 36.69 |
| August 26, 2024 | 37.07 |
| August 23, 2024 | 37.72 |
| August 22, 2024 | 37.43 |
| August 21, 2024 | 37.49 |
| August 20, 2024 | 37.38 |
| August 19, 2024 | 36.41 |
| August 16, 2024 | 36.44 |
| August 15, 2024 | 37.25 |
| August 14, 2024 | 36.85 |
| August 13, 2024 | 36.88 |
| August 12, 2024 | 35.24 |
| August 09, 2024 | 36.76 |
| August 08, 2024 | 34.73 |
| August 07, 2024 | 32.94 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
13.23
Minimum
Mar 23 2020
46.36
Maximum
Jun 25 2024
24.85
Average
23.53
Median
Price to Book Value Benchmarks
| Eli Lilly and Co | 60.92 |
| Genmab AS | 3.279 |
| Ascendis Pharma AS | -- |
| Galecto Inc | 0.3133 |
Price to Book Value Related Metrics
| PE Ratio | 39.70 |
| PS Ratio | 13.83 |
| PEG Ratio | 1.037 |
| Price to Free Cash Flow | 54.47 |
| Price | 115.70 |
| Earnings Yield | 2.52% |
| Market Cap | 514.93B |
| PEGY Ratio | 1.004 |
| Operating PE Ratio | 32.01 |
| Normalized PE Ratio | 39.70 |